Nimotuzumab

AbMole BioScience

Nimotuzumab

9

Antibody

Research Use Only

Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab failed to recognize mouse EGFR.

-80°C for long term

12352203